An official website of the United States government. Cite this: Skin Reactions After COVID-19 Vaccination . Pityriasis rosea (PR) is an acute, exanthematous disease likely caused by human herpesvirus (HHV)-6 and/or HHV-7. Case Report: Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination. As the worldwide vaccination campaign against the COVID19 pandemic continues, we emphasize that pityriasis rosea can result from new CoronaVac COVID19 vaccine, for both physicians and patients, and lesions may be reactivated after the second vaccination. Fortunately, PR-like eruption is responsive to topical corticosteroids without any systemic adverse effects. Dermatol Reports. J Eur Acad Dermatol Venereol. Reactions related to the hair have so far not been reported. 2022 Jan;114:88-89. doi: 10.1016/j.ijid.2021.10.055. It has been suggested that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces reactivation of other viruses, such as HHV-6, HHV-7, varicella zoster virus, and Epstein-Barr virus (5). Environ Sci Pollut Res. Contributions: SV and CAM, conceived and wrote the article. Seborrheic dermatitis is a skin condition that mainly affects the scalp, causing scaly patches of red skin and stubborn dandruff. JAAD Case Rep 2018; 4:8001. Spongiotic dermatitis was the most commonly reported cutaneous reaction to COVID-19 vaccination among patients who also had biopsy results available for review, according to a registry-based. J Eur Acad Dermatol Venereol. 2022 Feb 3;9 (2):003164. doi: 10.12890/2022_003164. J Formos Med Assoc. Patients characteristics are reported in Table 1. Accessibility We present a case of a pityriasis rosea-like rash occurring after Pfizer COVID-19 vaccination and review cases of pityriasis rosea (PR)/PR-like eruption (PR-LE) after mRNA COVID-19 vaccine published in the medical literature. The latter is found in a younger age group. Therefore, this study will systematically review its manifestation afteradministration. The .gov means its official. official website and that any information you provide is encrypted 2021 Aug;185(2):e34. MeSH The .gov means its official. Bookshelf Careers. Pityriasis rosea (PR)-like eruption is a cutaneous complication associated with several medications and vaccinations. Only a few cases of pityriasis rosea (PR)/pityriasis rosea-like eruption (PRLE) after anti-SARS-CoV-2 vaccination have been reported. Children often get infected when someone sneezes or kisses them. 7 Articles, This article is part of the Research Topic, Creative Commons Attribution License (CC BY), Division of Dermatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. Abdominal fullness prematurely after meals and Pityriasis rosea Please enable it to take advantage of the complete set of features! 2021 Dec;108(6):317-318. doi: 10.12788/cutis.0411. Pityriasis rosea-like eruption after Pfizer-BioNTech COVID-19 vaccination Pityriasis rosea-like eruption after Pfizer-BioNTech COVID-19 vaccination Pityriasis rosea-like eruption after Pfizer-BioNTech COVID-19 vaccination Pityriasis rosea-like eruption after Pfizer-BioNTech COVID-19 vaccination Br J Dermatol. Unable to load your collection due to an error, Unable to load your delegates due to an error. 2022 Sep-Oct;40(5):586-590. doi: 10.1016/j.clindermatol.2022.01.002. Epub 2022 Feb 9. 2022 Jul 6;15(1):9503. doi: 10.4081/dr.2022.9503. A 52-year-old Thai woman with a one-year history of recurrent glioblastoma was admitted to our hospital for a planned targeted therapy. PRISMA, preferred reporting items for systematic reviews and metaanalysis. World J Clin Cases. 8600 Rockville Pike Dermatol Res Pract. Br J Dermatol. It is also called Christmas tree rash. Pityriasis Rosea Treatment, Causes, Stages, Pictures & Herpes - MedicineNet FOIA It has been reported that pityriasis rosea has been triggered by several vaccines, as a rare side-effect. Pityriasis rosea. It is important for physicians to be aware of this self-limited reaction so they can reassure and appropriately counsel patients that it is safe to receive subsequent vaccine doses despite the cutaneous eruption. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). In the period May 2021- February 2022 we observed five cases of clinically typical PR that appeared 2 to 3 weeks after anti-SARS-CoV-2 vaccination with BNT162b2 (3 patients) or mRNA- 1273 (2 patients). reactions included pernio/chilblains, cosmetic ller reactions, zoster, herpes simplex ares, and pityriasis rosea-like reactions. 2021 Sep;35(9):e546-e548. Pityriasis Rosea | Cedars-Sinai eCollection 2022. National Library of Medicine . Future studies should investigate oral lesions in SARS-CoV-2-positive subjects and after COVID-19 vaccination in the pediatric population, taking into account viral variants and newly developed vaccines. After introducing Covid-19 vaccines, a few side effects were reported, pityriasis rosea being one of them. Pityriasis rosea, pityriasis rosea-like eruptions, and herpes zoster in Unauthorized use of these marks is strictly prohibited. In all patients PR was characterized by the appearance of a typical herald patch (Figure 1), followed, a few days later, by widespread, clinically similar, although smaller lesions. Pityriasis is linked mainly with herpesviruses 6 and 7; only a . Received 2022 Mar 26; Accepted 2022 Apr 25. 2023 Apr;11(4):e804. Pityriasis rosea after administration of Pfizer-BioNTech COVID-19 vaccine Pityriasis rosea (PR) is an acute papulosquamous cutaneous disorder that classically presents with a herald patch rapidly followed by a widespread rash along skin cleavage lines. If so, the reason may be simple: in several countries, BNT162b2 is the most used vaccine; iii) in 55 cases the rash was classified as PR, in 6 cases as PRLE; iv) in 39 cases the eruption appeared 1-12 days after the first dose (around: 4.8 days). The rash can be itchy. COVID-19 is an infectious disease caused by SARS-CoV-2, which emerged in China in 2019 and rapidly spread worldwide to become a pandemic in March 2020. the reactivation of varicella zoster or herpes simplex infections, pityriasis rosea or rosea-like lesions, petechiae, pernicious purpura . Accessibility All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. 2021;185(2):e34. Would you like email updates of new search results? Researchers Continue to Find Clues About MIS-C - Yale Medicine Pityriasis rosea, COVID-19 and vaccination: new keys to understand an old acquaintance. Pityriasis rosea after mRNA COVID-19 vaccination Pityriasis rosea after mRNA COVID-19 vaccination Pityriasis rosea after mRNA COVID-19 vaccination Pityriasis rosea after mRNA COVID-19 vaccination Int J Dermatol. Before PMC (PDF) Gianotti-Crosti Syndrome in a Child with Recent Covid-19 Pearls and pitfalls: Adverse cutaneous reactions after COVID-19 vaccination. 2021 Jul;85(1):46-55. doi: 10.1016/j.jaad.2021.03.092. Although the exact pathogenesis of PR remains unknown, the endogenous systemic reactivation of HHV (i.e., type 6 and 7) in the skin has been implicated as a precipitating factor. In conclusion, we have described the first case of PR-like eruption following ChAdOx1 nCoV-19 (Oxford/AstraZeneca) vaccination. doi: 10.1111/jdv.12942, 13. Although it is known that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be associated with skin manifestations, a limited number of images are available in the literature at this time. Keywords: (2006) 12:1. doi: 10.5070/D380D8301D, 11. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. They described a patient developing pityriasis rosea (PR) 2 hours after the second dose of Moderna COVID-19 vaccination. However, after 14 days, she developed multiple discrete blanching erythematous oval patches and plaques on the lower abdomen, back, and bilateral upper thighs (Figures 1A,B). Would you like email updates of new search results? J Eur Acad Dermatol Venereol 2016; 30: 544-545. (2021) 60:11501. 21% of people who have Covid develop a rash as their only symptom of infection. The coronavirus disease 2019 (COVID-19) pandemic is filling the headlines these days. Wien Med Wochenschr. Vaccine-induced pityriasis rosea and pityriasis rosea-like eruptions: a review of the literature. Pityriasis rosea and pityriasis rosea-like eruption after anti-SARS-CoV-2 vaccination: a report of five cases and review of the literature. No HHV-6 and HHV-7 reactivation is detected. Pityriasis is linked mainly with herpesviruses 6 and 7; only a small number of cases have been reported in association with vaccinations (e.g., yellow fever, influenza, hepatitis B, human. Other plausible theories include molecular mimicry with viral epitopes and type IV delayed hypersensitivity reaction (12). Learning points: Drago F, Ciccarese G, Rebora A, et al. Epub 2021 Nov 2. 2023 Apr;11(4):e804. Epub 2022 Jan 31. Lasers Med Sci. Dermatol Ther. As with eczema, the conditions can be differentiated under the microscope by their acanthotic or non-acanthotic appearance. SARS-CoV-2 spike protein positivity in pityriasis rosea-like and urticaria-like rashes of COVID-19. (2017) 5:20311. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (, Anti-SARS-CoV-2, AZD1222, BNT162b2, mRNA-1273, Pityriasis rosea, Pityriasis rosea-like eruption. Only a few cases of pityriasis rosea (PR)/pityriasis rosea-like eruption (PRLE) after anti-SARS-CoV-2 vaccination have been reported. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. J Invest Dermatol. 2021;23(3):221228. Pityriasis Rosea as a Possible Complication of Vaccination Against COVID-19 Since you said you felt ill at the time getting the vaccine you had covid at the time. Zhongguo Dang Dai Er Ke Za Zhi. -. Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 Vaccine. The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s. In a 2020 analysis of 171 patients with laboratory-confirmed COVID-19 and cutaneous manifestations from the registry, the most commonly reported cutaneous manifestations were morbilliform rash (22 percent), pernio-like acral lesions (18 percent), urticaria (16 percent), macular erythema (13 percent), vesicular eruption (11 percent),